PROJECT
Our values are equity, solidarity, sustainability and innovation.
Overview
HORUS involves the first longitudinal cohort of European SOT recipients. In a sub-‘HORUS-exploratory cohort’, we will perform a thorough investigation of viral, clinical and immunological characteristics.
Combining those parameters will provide a signature early after transplantation to predict the risk of developing CMV infection and a signature at Day 0 of infection to predict the risk of CMV disease severity.
This signature will then be validated retrospectively by the whole cohort and prospectively in a ‘proof-of-concept’ study. Moreover, HORUS will include functional in vitro and mouse models to investigate the mechanisms of lymphocyte response to CMV and provide innovative methods to increase CMV-specific immunity.
Altogether, HORUS will enhance personalised clinical prevention and the treatment of CMV disease, ultimately improving patient outcomes.
Project Updates
Patient recruitment is close to completion, with the first biosamples sent off to the scientific partners for analysis in Work Packages 2 and 3.
Stay tuned for more updates and messages from the team behind the research!
